Accueil   Diary - News   All news Biom’up finalizes U.S. commercial organization to support U.S. launch of HEMOBLASTTM Bellows

Biom’up finalizes U.S. commercial organization to support U.S. launch of HEMOBLASTTM Bellows



  • U.S. team of more than 100 specialist sales representatives & seasoned management in place


  • On track with clinical, regulatory, financial, and commercial milestones



Saint-Priest, France, May 2, 2018 – Biom'up (EPA: BUP), a specialist in surgical hemostasis, today announced it has finalized the commercial infrastructure to support the imminent launch of its lead product HEMOBLAST Bellows. The Company has recruited senior management and a large number of independent specialist sales representatives to drive the nationwide marketing and sales campaign of HEMOBLAST Bellows, which is expected to start in mid-2018.

Etienne Binant, Chief Executive Officer, said: “Under the leadership of Dave Clark, U.S. Vice President of Sales, and Steven Ford, U.S. Vice President of Marketing, we have swiftly built a dedicated national hybrid sales organization. With a large team of specialists now in place, and given its clinically demonstrated high value, we are confident that HEMOBLAST Bellows will make substantial inroads and become a fixture of hemostasis in operating rooms across the USA. Biom’up is now perfectly positioned to pursue its growth ambitions and transition towards a fully-fledged commercial organization.



Read the full press release




By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to More details are available by clicking here I agree